Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer

Launched by GEORGETOWN UNIVERSITY · May 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a special decision aid website can help patients with intermediate-risk thyroid cancer make informed choices about radioactive iodine (RAI) treatment. The goal is to see if this website makes it easier for patients to understand the benefits and risks of RAI and to make choices that reflect their personal values. Participants in the trial will be divided into two groups: one group will use the decision aid website, which includes interactive tools, videos, and exercises to help clarify their preferences, while the other group will use a standard website from the American Cancer Society that provides basic information without interactive features.

To be eligible for this trial, participants must be 18 years or older, diagnosed with intermediate-risk differentiated thyroid cancer within the last six months, and ready to decide about RAI treatment. They should also be able to understand the information being shared and ask questions if needed. Throughout the study, which involves regular surveys over six months, participants will learn more about their treatment options and how to communicate effectively with their healthcare team. Importantly, while the decision aid is there to support patients, discussions with doctors remain a vital part of the treatment decision process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 and older
• • Patients diagnosed with intermediate risk DTC \< 6 months ago and who are making a decision about RAI treatment
• • Ability to understand the information conveyed in the informed consent form, pose questions and process answers (e.g., no cognitive impairment per direct consultation with the patient's physician), and, finally, provided informed consent to participate.
• • Participants willingness to be contacted and remain available to complete study activities throughout the duration of the study.
• Exclusion Criteria:
• • Diagnosis of low risk or high risk DTC
• • Prior history of RAI
• • Clinical contraindications that prevent consideration of RAI (e.g., pregnancy, lactation, neutropenia if considering high dose of RAI)